Changes in laboratory markers of thrombotic risk early in the first trimester of pregnancy may be linked to an increase in estradiol and progesterone by Bagot, C.N. et al.
  
 
 
 
 
Bagot, C.N., Leishman, E., Onyiaodike, C.C., Jordan, F., Gibson, V.B. and Freeman, 
D.J. (2019) Changes in laboratory markers of thrombotic risk early in the first trimester 
of pregnancy may be linked to an increase in estradiol and progesterone. Thrombosis 
Research, 178, pp. 47-53. (doi: 10.1016/j.thromres.2019.03.015)  
 
There may be differences between this version and the published version. You are 
advised to consult the publisher’s version if you wish to cite from it. 
 
 
 
http://eprints.gla.ac.uk/185027/ 
      
 
 
 
 
 
Deposited on: 19 August 2019 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Changes in Laboratory Markers of Thrombotic Risk Early in the First Trimester of Pregnancy may 
be Linked to an Increase in Estradiol and Progesterone 
CN Bagot1, E Leishman1, CC Onyiaodike2, F Jordan2, VB Gibson1, DJ Freeman2 
1Department of Haematology, Glasgow Royal Infirmary, Glasgow UK; 2Institute of Cardiovascular 
and Medical Sciences, University of Glasgow, Glasgow UK 
 
Keywords: pregnancy, thrombin, thrombosis, estradiol, progesterone 
Abstract 
Background 
Pregnant women are at increased risk of venous thrombosis compared to non pregnant women. 
Epidemiological and laboratory data suggest that hypercoagulability begins in the first trimester but 
it is unknown exactly how early in pregnancy this develops. The mechanisms that result in a 
prothrombotic state may involve oestrogens and progestogens. 
Methods 
Plasma samples were taken prior to conception and five times in early pregnancy, up to Day 59 
gestation, from 22 women undergoing natural cycle in vitro fertilization, who subsequently gave 
birth at term following a normal pregnancy.  
Thrombin generation, free Protein S, Ddimer, Fibrinogen, factor VIII, estradiol and progesterone 
were measured.  To counter inter-individual variability, the change in laboratory measurements 
between the pre-pregnant and pregnant state were measured over time.  
Results 
Peak thrombin, Endogenous Thrombin Potential, Velocity Index and fibrinogen significantly 
increased, and free Protein S significantly decreased, from pre-pregnancy levels, by 32 days 
gestation. Ddimer and VIII significantly increased from pre-pregnancy levels by 59 days gestation. 
Estradiol significantly increased by Day 32 gestation with a non-significant increase of 67% by Day 24 
gestation. Progesterone significantly increased by Day 32 gestation. Almost all laboratory markers of 
thrombosis correlated significantly with estradiol and progesterone.  
Conclusion 
Our work is the first to demonstrate that the prothrombotic state develops very early in the first 
trimester. Laboratory markers of hypercoagulability correlate significantly with estradiol and 
progesterone suggesting these are linked to the prothrombotic state of pregnancy. Clinicians should 
consider commencing thromboprophylaxis early in the first trimester in women at high thrombotic 
risk.  
 
 
 
 
 
 
 
 
 
 
 
 Introduction 
Pregnancy is a prothrombotic state, likely arising from a physiological response to reduce the risk of 
bleeding during the antenatal, and particularly the post natal, period. As a result, pregnant women 
are at increased risk of venous thrombosis compared to the general population. Epidemiological 
data suggests that hypercoagulability begins early in pregnancy, with an increase in thrombotic risk 
beginning in the first trimester 1-3. However, it is unknown exactly how early in pregnancy that the 
hypercoagulable state begins to develop.  
 
In a number of studies a significant proportion of antenatal venous thromboembolism (VTE) is 
reported to occur in the first trimester, with reported figures ranging between 11-21% of all 
antenatal VTE 4-6. One study that particularly assessed the proportion of VTE occuring in each 
trimester reported that 44% of antenatal VTE occurred in the first trimester 2. Furthermore, data 
from the UK maternal mortality database (MBRRACE-UK) indicates that 50% of antenatal deaths 
occur in the first trimester 7.  Finally, studies sometimes do not include women prior to 13 weeks 
gestation or exclude women with pregnancy losses (spontaneous, therapeutic or as a result of 
ectopic pregnancy) 4, 5. As a result of this and given that most pregnancy losses occur in the first 
trimester, the risk of VTE in the first trimester is likely significantly underestimated.   
 
There are some well recognised changes in coagulation factor concentrations that occur during 
pregnancy. The concentration of Protein S, both total and free (the latter being the active form), 
decreases during pregnancy, resulting in a decrease in the downregulation of activated factors V and 
VIII 8-12. An increase in factor VIII also occurs, likely secondary to both reduced Protein S and 
increased VWF levels, the latter extending the half life of FVIII 8, 9, 12 . Fibrinogen, the precursor to 
fibrin, the main constituent of a thrombus, is increased during pregnancy 9. Perhaps to counteract 
this increase in the plasma concentration of fibrinogen, there is increased fibrin turnover resulting in 
an increase in fibrin degradation products, such as ddimer [remove some refs?] 13-17. Despite these 
characterizations, the time at which these changes first occur during pregnancy is unknown. 
 
Thrombin generation, a global coagulation assay, has been demonstrated to more accurately reflect 
the thrombotic phenotype than measuring individual parameters of the coagulation cascade 18-22. 
Thrombin is pivotal to the coagulation cascade; it is the enzyme responsible for converting 
fibrinogen to fibrin, the step resulting in clot formation. Thrombin also has numerous positive and 
negative feedback roles across the coagulation cascade, thus making it central to this process. It is 
therefore reasonable to expect that an assessment of an individual’s ability to generate thrombin 
will provide an accurate evaluation of an individual’s potential to coagulate. 
 
Studies assessing thrombin generation during pregnancy have been undertaken but have had 
various limitations in their findings 21, 23-25. Rarely has thrombin generation been assessed earlier 
than 10 weeks of gestation and most studies have not obtained pre-pregnancy samples from the 
same women, preventing an account to be taken of the known significant inter-individual variability 
in thrombin generation 21, 25-30. Other potential confounders such as the use of low molecular weight 
heparin (LMWH) have also affected data 28, 29. 
 
We have recently demonstrated that thrombin generation, using any of the four most recognised 
assay conditions, increases from approximately the 5th gestational week 31. This data was obtained 
from a cohort of women undergoing natural cycle in vitro fertilization, as such women provide the 
most practical method of obtaining accurately timed peri–conceptual and early pregnancy samples 
and are the best physiological representation of a ‘normal’ pregnancy, outside a free living 
population. These women subsequently gave birth at term following a normal pregnancy. This was 
the first study to assess thrombin generation during the first few weeks of pregnancy, use pre 
pregnancy samples from the same women as internal comparators, use internal quality controls and 
avoid confounders such as low molecular weight heparin (LMWH). We therefore believe that this is 
the most valid and accurate measurement of thrombin generation in early pregnancy to date. 
 
The mechanism by which a prothrombotic state develops in pregnancy may involve estrogens and 
progestogens, whose levels are known to change during pregnancy. It is hypothesised that the 
prothrombotic state may develop secondary to increased levels of estradiol, this argument being 
strengthened by the increased risk of venous thrombosis and similar alterations of coagulation 
parameters in women exposed to exogenous estrogens contained within the combined oral 
contraceptive pill (COCP) and hormone replacement therapy (HRT) 22, 32-34. During pregnancy, 
estradiol production increases significantly, initially through secretion from the corpus luteum and 
towards the end of the first trimester, this role is taken over by the placenta 35. Estrogen response 
elements (ERE) have been demonstrated upstream of many genes encoding for coagulation factors 
in the liver and exposure to estradiol affects coagulation factor transcription 36-40. Taken together, 
these data make estradiol a prime candidate to investigate as a potential cause of the prothrombotic 
changes detected in the plasma of pregnant women. Progestogens also are linked to thrombosis 
risk, albeit this being much weaker than the link with estrogens. This link is mainly via 
epidemiological data from women exposed to exogenous progestogens in the COCP and HRT 41-46. 
 
In this study we assessed the same cohort of women undergoing natural cycle in vitro fertilization, as 
previously described, to determine whether, alongside thrombin generation, levels of well 
recognised laboratory features of the prothrombotic state of pregnancy e.g. FVIII, ddimer, fibrinogen 
and protein S change at a similar stage of pregnancy as thrombin generation.  We investigated 
whether these coagulation factors correlate with thrombin generation when using what is 
considered to be the most ‘sensitive’ thrombin generation assay method i.e. 1pM TF with 
thrombomodulin where both the intrinsic, extrinsic and activated Protein C (APC) pathways are 
included in the assessment. To establish a potential mechanism for any change in thrombotic 
markers early in pregnancy, levels of estradiol and progesterone were also measured over the same 
time period.  
 
Our aim was to demonstrate how early in pregnancy laboratory markers of the prothrombotic state 
begin to develop, to establish a potential mechanism for these changes and in turn, guide clinicians 
as to how early preventative measures should be taken in pregnant women at high risk of 
thrombosis.  
  
Materials and Methods 
Participants 
Women undergoing natural cycle in vitro fertilization (i.e. no hormonal treatment), were recruited 
from the Assisted Conception Service at Glasgow Royal Infirmary between October 2007 and June 
2010. Demographic data was collected and blood samples taken pre-pregnancy and during the very 
early stages of pregnancy. Women were subsequently followed up throughout pregnancy and to 
delivery. Only women who developed no pregnancy complications, received no concomitant 
anticoagulant therapy throughout pregnancy and delivered a normal baby at term were included in 
the final analysis. 
The study had full ethical and R&D approval from Glasgow Royal Infirmary Research and Ethics 
Committee (Ref. No. 07/S0704/49) and Research and Development Office (Ref. No. RN07OB005). 
Written informed consent was obtained for every participant. 
 
Sample Collection 
Venous blood was collected into 0.109 M sodium citrate or 0.369 M tripotassium EDTA and 
centrifuged at 3000 rpm for 15 minutes at 4°C within 2 hours of collection. Citrated plasma was spun 
a second time in a microfuge at 13,000 rpm for 4 minutes to obtain platelet poor plasma (PPP). All 
plasma was stored at -80°C.   
Within the study, Study Day -3 was considered to be equivalent to Day 14 from last menstrual period 
(LMP) in a naturally occurring pregnancy (i.e. 2 weeks gestation assuming a 28 day menstrual cycle). 
Pre-pregnancy samples were taken approximately at the time of the lutenizing hormone surge 
(Study Day -3) and at the time of frozen embryo transfer (Study Day 0). Up to a further 5 samples 
were then taken from the same women very early in gestation, at Study Day +4, +7, +15, +26 and 
+42, with Study Day +42 being equivalent to estimated Day 59 gestation (Figure 1). 
 Figure 1 Sample Time Points and Equivalent Gestational Period 
LH: lutenizing hormone; FET: frozen embry transfer; hCG: human chorionic gonadotrophin
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Laboratory Investigations 
All measurements were carried out at Glasgow Royal Infirmary, with samples from each 
woman assessed concurrently to minimise the effect of inter-assay variability. Commercial 
reagents were used according to the manufacturers’ instructions.  
 
Thrombin Generation 
Thrombin generation (TG) was measured using the Calibrated Automated Thromobogram 
method (CAT, Thrombinoscope, BV, Maastricht, Netherlands) as described previously 31. 
Briefly, 80 µl of platelet poor plasma were mixed with 20 µl PPPLow (1 pM tissue factor 
[TF]), in the presence of 0.4 nM thrombomodulin (TM) and 20 µl FluCa solution, where the 
optimal concentration of TM used was determined as described 47. TG reagents were 
purchased from Diagnostica Stago (Asnières, France), TM was donated by Cardiovascular 
Research Institute Maastricht (CARIM), The Netherlands and TGT Reference plasma (TGT-
RP) was a gift from NIBSC (Potters Bar, Hertfordshire, UK). TG parameters measured were; 
time to the first thrombin production (lag time), the maximum concentration of thrombin 
generated (Peak Thrombin), the slope between first thrombin production and the time to 
achieve Peak Thrombin (Velocity Index),time to reach peak height (ttPeak), time at which 
thrombin generation ceases (start tail) and the area under the curve (Endogenous Thrombin 
Potential, ETP).  
 
Estradiol and Progesterone 
Estradiol and progesterone levels were determined with the commercially available 
chemiluminescent microparticle immunoassay kits; Architect Estradiol 7K72 and Architect 
Progesterone 7K77, using the architect iSR 2000 machine (Abbott Diagnostics). 
 
Other Laboratory Measurements 
For all other coagulation assays, reagents were purchased from Instrumentation Laboratory 
and the automated analyser ACL TOP 700 was used. Protein S and D-Dimer were measured 
by automated latex enhanced immunoassays using Free Protein S and D-Dimer HS Kits. 
Fibrinogen levels were measured by the Clauss method, using QFA-Fib, and FVIII was 
measured by a one-stage clotting assay, with Factor VIII deficient plasma and Synthasil 
(APTT Reagent). 
 
Statistical Analysis 
Data are expressed as percentage change from baseline (pre-pregnancy) and reported as mean ± 
95% confidence interval (C.I.) for parametric and median + interquartile range for non-parametric 
data. Statistical analyses were performed using GraphPad Prism. To compare results between study 
time points for each laboratory measurement, for parametric data ANOVA followed by Dunnett’s 
multiple comparison tests were used, and for non-parametric data a Kruskal-Wallis test was used. 
Spearman’s rank correlation was used to assess the association between laboratory measurements. 
Statistical significance was given a P-value of < 0.05. 
 
Results 
196 women were recruited, with 36 successful first attempt pregnancies, of which 22 women gave 
birth at term with no complications occurring during the antenatal period. Demographic data for 
these 22 women is shown in Table S1, including the reason for IVF. 
 
 
 
  
 
Characteristics Mean (95% C.I.) or n (%) 
Age (years) 34.6 (32.4, 36.8) 
Current smoker n (%) 2 (9%) 
SIMD quintile 
1- Most affluent, 5- most deprived 
1 
2 
3 
4 
5 
 
 
3 (14%) 
5 (23%) 
4 (18%) 
5 (23%) 
5 (23%) 
SBP (mmHg) 118 (112, 124) 
DBP(mmHg) 65 (62, 69) 
Height (m) 1.7 (1.6, 1.7) 
Weight (kg) 73.0 (67.3, 78.6) 
BMI (kg/m2) 27.0 (24.8, 29.1) 
Waist (cm) 90.1 (85.2, 95.0) 
Menstrual period length (days) 4.4 (3.7, 5.1) 
Cycle length (days) 29.0 (28.2, 29.9) 
Number of previous pregnancies ≥24 weeks 
0 
1 
2 
 
22 (100%) 
0 (0%) 
0 (0%) 
Number of previous pregnancies <24 weeks 
0 
1 
2 
3 
 
14 (64%) 
4 (18%) 
3 (14%) 
1 (5%) 
Number of embryos transferred 
1 
2 
3 
 
5 (23%) 
16 (73%) 
1 (5%) 
Reason for infertility n (%) 
Male 
Female 
 
9 (40.9%) 
13 (59.1%) 
Treatment 
IVF 
ICSI 
 
13 (36%) 
23 (64%) 
 
Table S1: Demographic Data 
SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; C.I.: confidence 
intervals; SIMD: Scottish index of multiple deprivation; IVF: in vitro fertilization; ICSI: intra-
cytoplasmic sperm insemination 
  
Effect of Pregnancy on Thrombin Generation 
Thrombin generation was measured in 19 separate experiments, where all samples from each 
individual woman were assessed concurrently to limit the effect of inter-assay variability and were 
tested in parallel with TGT-RP. Intra-assay coefficient of variation (CV) for TGT-RP was less than 5% 
for all TG parameters (data not shown). 
 
On analysis of the mean raw data at study time points, there was a significant increase at Study Day 
+26 (approximately Day 43 gestation) from baseline (average of Study Days 0 & 3 [pre-pregnancy]) 
for mean peak thrombin and mean ETP. This increase persisted to Study Day +42 (approximately 
gestational day 59). To minimise the effect of inter-individual variability, the mean change in 
thrombin generation over time was also determined i.e. change between the pre-pregnant and 
pregnant state per individual. There was a significant change from baseline (pre-pregnancy) at Study 
Day +15 (approximately Day 32 gestation) for peak thrombin, ETP and VI. This increase persisted into 
the 6th and 8th gestational week (Study Days +26 & +42 respectively). Table 1 summarises all mean 
raw data generated for ETP, peak and VI. Figure 2 illustrates the data for mean percentage change 
from baseline. The women’s data normalised to results from the standard plasma (TGT-RP) 
produced identical/very similar statistically significant outcomes (data not shown)
 Day -3  
(n=21) 
Day 0  
(n=22) 
Day +4              
(n=13) 
Day +7           
(n=12) 
Day +15            
(n=22) 
Day +26            
(n=16) 
Day +42                  
(n=19) 
ETP 
(nM.min) 
894                 
(768, 
1019) 
760             
(621, 898) 
923                         
(717, 
1130) 
1007                       
(839, 
1175) 
1019                  
(877, 
1161) 
(c) 1186                 
(1019, 
1352) 
(d) 1278                
(1144, 
1413) 
Peak 
thrombin 
(nM) 
167            
(137, 197) 
136            
(107, 165) 
172                  
(127, 217) 
186                       
(151, 222) 
190                 
(161, 218) 
(b) 211                   
(177, 246) 
(c) 230                       
(201, 260) 
Velocity 
Index 
52              
(39, 64) 
41                      
(30, 52) 
53                             
(37, 70) 
59                       
(43, 76) 
61                                
(49, 72) 
66                   
(51, 80) 
(b)72                    
(59, 86) 
 
Table 1: Thrombin generation mean raw data for pre-pregnancy and early pregnancy. 
Mean raw data for ETP, peak and velocity Index between pre-pregnancy and early pregnancy. Pre-
pregnancy values are an average of Study Day -3 and Study Day 0. Each box represents the mean 
value with 95% confidence intervals in brackets. (a) represents p<0.05; (b) represents p<0.01; (c) 
represents p<0.001; (d) represents p<0.0001. P represents the comparison between the mean at 
baseline (average of Day -3 and Day 0) and the mean at individual time points during early 
pregnancy. P values are based on ANOVA for continuous variables. n= number of samples available 
for analysis at that time point. n/a = not applicable, ETP: endogenous thrombin potential. 
 
 
Figure 2. Mean percentage change from baseline in early pregnancy in thrombin generation at 
1pM TF + TM 
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Mean data +/- 95% C.I. for percentage change from baseline under 1pM TF+ TM assay conditions. 
Baseline is the mean of Study Day -3 and Study Day 0. Change from baseline is the change in a 
thrombin generation parameter between baseline and a given time point in early pregnancy e.g. Day 
+15 compared to baseline. ** represents p<0.01; ***represents p<0.001; **** represents p<0.0001. 
TF: tissue factor; TM: thrombomodulin; ETP: endogenous thrombin potential 
 
 
Other Laboratory Measurements 
Protein S demonstrated a significant reduction from baseline by Study Day +15 (approximately Day 
32 gestation) (p<0.01), and this decrease persisted to gestational Day 59. Similarly, fibrinogen 
changed significantly by Study Day +15 (approximately Day 32 gestation) (p<0.01), with an increase 
from baseline, and this persisted to gestational Day 59. D-dimer and FVIII also increased significantly 
(p<0.0001) by Study Day +42 (approximately Day 59 gestation) as shown in Table 2 and Figure 3. 
 
 
 
 
 
 
 
  
  
Baseline  
(n=22) 
Day +4              
(n=13) 
Day +7           
(n=12) 
Day +15            
(n=22) 
Day +26            
(n=16) 
Day +42                  
(n=19) 
Estradiol  
(pmol/l) 
374  
(428) 
453  
(184) 
491  
(274) 
(b) 650  
(454) 
(d) 1362 
(805) 
(d) 3194 
(2645) 
Progesterone 
(nmol/l) 
1 n/t n/t 
(d) 69.35 
(71.1) 
(d) 69.2 
(50.3) 
(d) 58.5 
(29.6) 
Protein S  
(%) 
109.25 
(17.3) 
109  
(18.1) 
102.05 
(16.4) 
92.05  
(4.5) 
(c) 71.3 
(24.9) 
(d) 48.8 
(24.6) 
D-Dimer 
(ng/ml) 
46.5  
(60) 
(a)121  
(59) 
73.5  
(12) 
88  
(51.3) 
109  
(73) 
(b) 131  
(67) 
Fibrinogen  
(g/l) 
2.6  
(2.3) 
2.8  
(0.9) 
2.73  
(0.4) 
3.36  
(0.6) 
3.16  
(0.4) 
(b) 3.59 
(0.6) 
FVIII 
(%) 
95.9  
(26.5) 
95.55  
(16.9) 
88.57  
(10.8) 
102.8  
(27.7) 
95.6  
(22.7) 
(a) 125.5 
(52.45) 
 
Table 2: Median raw data for Estradiol, Progesterone, Protein S, D-Dimer, Fibrinogen and FVIII.  
Median raw data between pre-pregnancy and early pregnancy for Estradiol, Progesterone, Protein S, 
D-Dimer, Fibrinogen and FVIII. Pre-pregnancy values are an average of Study Day -3 and Study Day 0. 
Each box represents the median value with the interquartile range in brackets. n/a = not applicable, 
n/t = not tested, (a) represents p<0.05; (b) represents p<0.01; (c) represents p<0.001; (d) represents 
p<0.0001. P represents the comparison between the mean at baseline (average of Day -3 and Day 0) 
and the mean at individual time points during early pregnancy. P values are based on the Kruskal-
Wallis test for continuous variables. n= number of samples available for analysis at that time point.  
 
 Figure 3. Mean percentage change from baseline in early pregnancy in Estradiol, Progesterone, 
Protein S, D-Dimer, Fibrinogen and FVIII 
Mean data +/- 95% C.I. for percentage change from baseline. Baseline is the mean of Study Day -3 
and Study Day 0. Change from baseline is the change in a thrombin generation parameter between 
baseline and a given time point in early pregnancy e.g. Day +15 compared to baseline. ** represents 
p<0.01; ***represents p<0.001; **** represents p<0.0001. 
 
Estradiol and Progesterone 
Estradiol significantly increased by Study Day +15 (approximately Day 32 gestation) with a non-
significant increase of 67% by Study Day +7 (Figure 3). Progesterone significantly increased by Study 
Day +15 (approximately Day 32 gestation).  
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Correlation between thrombin generation parameters, other coagulation factors and estradiol and 
progesterone 
The thrombin generation parameters ETP, Peak thrombin and Velocity Index, correlated significantly 
with estradiol (Figure 4) and all other laboratory markers measured (Table 3). All the laboratory 
markers measured correlated significantly with Estradiol and with each other with the exception of 
Progesterone, where correlation with Estradiol and FVIII was not significant (Table 4). 
 
 
 
 
Figure 4.  Correlation of Estradiol with Thrombin Generation Parameters ETP, Peak and Velocity 
Index under 1pM TF+ TM. 
Percentage change from baseline is the change between baseline and a given time point in early 
pregnancy. TF: tissue factor; TM: thrombomodulin; ETP: endogenous thrombin potential 
 
 
 
 
 
-100 -50 0 50 100 150 200
-1000
0
1000
2000
3000
Estradiol & ETP@1pM+TM
ETP @ 1pM TF+TM
% Change from Baseline
Es
tra
di
ol
%
C
ha
ng
e
fro
m
Ba
se
lin
e
Spearman r
r
95% confidence interval
P value
P (two-tailed)
P value summary
0.6465
0.5241 to 0.7428
<0.0001
****
-100 0 100 200 300
-500
0
500
1000
1500
2000
2500
Estradiol & Velocity Index @1pM+TM
Vel Index @ 1pM TF+TM
% Change from Baseline
Es
tra
di
ol
%
C
ha
ng
e
fro
m
Ba
se
lin
e
Spearman r
r
95% confidence interval
P value
P (two-tailed)
P value summary
0.5697
0.4299 to 0.6829
<0.0001
****
-100 0 100 200
-1000
0
1000
2000
3000
Estradiol & Peak @1pM + TM
Peak @ 1pM TF + TM
% Change from Baseline
Es
tra
di
ol
%
C
ha
ng
e
fro
m
Ba
se
lin
e
Spearman r
r
95% confidence interval
P value
P (two-tailed)
P value summary
0.6112
0.4804 to 0.7154
<0.0001
****
 Estradiol Progesterone Protein S Fibrinogen D-dimer Factor VIII 
 r p value r p value r p value r p value r p value r p value 
ETP 0.6465 <0.0001 0.4979 <0.0001 -0.6060 <0.0001 0.5029 <0.0001 0.3270 0.0090 0.5138 0.0001 
Peak 0.6112 <0.0001 0.4874 <0.0001 -0.5233 <0.0001 0.4682 0.0001 0.3460 0.0055 0.4656 0.0001 
Vel Index 0.5697 <0.0001 0.4104 0.0011 -0.4440 0.0003 0.4415 0.0003 0.3496 0.0050 0.4517 0.0002 
 
Table 3.  Correlation between parameters of thrombin generation, other markers of coagulation 
and the hormones, estradiol and progesterone 
 
 
 Estradiol Progesterone Protein S Fibrinogen D-dimer 
 r p value r p value r p value r p value r p value 
Progesterone 0.4692 0.0002         
Protein S -0.5833 <0.0001 -0.6521 <0.0001       
Fibrinogen 0.6200 <0.0001 0.8306 <0.0001 -0.6456 <0.0001     
D-Dimer 0.4908 <0.0001 0.5561 0.0006 -0.3977 0.0011 0.6121 <0.0001   
Factor VIII 0.3173 0.0120 0.3334 0.0579 -0.2782 0.0260 0.3419 0.0057 0.2906 0.0198 
 
Table 4. Correlation between laboratory markers of coagulation and the hormones, estradiol and 
progesterone 
 Discussion 
We have demonstrated for the first time the very early stage at which laboratory markers of 
coagulability change in pregnancy. Protein S, fibrinogen, ddimer and FVIII have previously been 
known to be affected by pregnancy but this is the first work to show how early in pregnancy these 
markers change. Furthermore, thrombin generation has also been shown to increase during 
pregnancy and our previous recent work demonstrated that thrombin generation, under all of the 
well recognised assay conditions, increases early in pregnancy, around the 5th week of gestation 31. 
 
Our current work has demonstrated that the procoagulant state of pregnancy begins within the first 
few weeks of gestation, with a decrease in Protein S alongside a concurrent increase in fibrinogen, 
ddimer, FVIII and thrombin generation. All of the changes in the coagulation factors occurred at a 
similar time and their levels correlated, suggesting a similar mechanism for all of them changing to a 
more thrombotic profile. The correlation of thrombin generation parameters with all of these 
coagulation factors is further evidence that thrombin generation can give a global overview of the 
coagulation status of a patient.  
 
The development of a prothrombotic profile appears to start at the beginning of the 5th gestational 
week as there is clearly a significant change in thrombin generation, Protein S and ddimer at this 
time. However, these changes may be occurring even earlier as the quantity of plasma available at 
Study Day +7 was small as not all women had sufficient plasma samples available for analysis at each 
time point. For example, Protein S and fibrinogen had changed by approximately 20% and ddimer by 
50% from baseline to Study Day +7 (approximately 24 days gestation) despite plasma only being 
available from 4 women at that time. With plasma samples available from more women at this time, 
an earlier significant change may have been seen. 
 
Estradiol increased significantly from baseline at approximately 4 weeks gestation, at the same time 
as the changes seen in the coagulation factors. However, for the reasons given above, that not every 
women had sufficient plasma samples available for analysis at every time point, it is highly likely that 
these changes occurred at an earlier gestation. From approximately 4 weeks gestation, the increase 
in estradiol from the pre pregnancy state was 67%, a substantial rise, highly suggestive that with 
greater numbers, it would have been possible to demonstrate that estradiol increases significantly 
enough to subsequently have an impact on coagulation factor gene expression.  
 
It is the data regarding correlation between all the coagulation factors, estradiol and progesterone 
which provides the strongest evidence for a relationship between these proteins. All the significantly 
increased thrombin generation markers correlated significantly with all the other coagulation factors 
and the individual coagulation factors correlated with each other. Perhaps most interestingly there 
was a strong correlation between estradiol and all the coagulation parameters, including thrombin 
generation, suggesting a relationship between the increased production of estradiol during early 
pregnancy and changes in coagulation protein levels. Estrogen response elements (ERE) have been 
demonstrated upstream of a number of coagulation factor genes, providing a hypothetical 
mechanism by which estradiol can alter coagulation factor gene expression 36-39. The Protein S gene 
has been demonstrated to have a near consensus ERE through which an effect on Protein S 
expression could occur but is unknown why estradiol would downregulate some coagulation factors 
e.g. Protein S and upregulate others 48. However, through evolutionary mechanisms, such regulation 
has resulted in a prothrombotic state possibly to reduce the risk of bleeding during the ante-, peri- 
and post partum periods and in turn reduce maternal morbidity and mortality from bleeding. 
Overall, given the EREs present upstream of many coagulation factors and the known changes in 
coagulation on exposure to exogenous estrogens, this work has provided further evidence for the 
role that estrogens play in the development of the prothrombotic state.  
There also appears to be a potential role for progestogens in the development of the prothrombotic 
state. Firstly, progestogens have been shown to affect coagulation factor expression in cell culture 
resulting in a prothrombotic phenotype and clinically it is known that certain exogenous 
progestogens alter thrombotic risk, with type and dose being important modifiers of risk 41-44, 49. 
Progestogens do not appear to have a direct effect on ERE expression but appear instead to have a 
modifying effect 50, 51. However, a direct effect is seen at high doses and this may be the reason why 
high dose norethistrone is directly prothrombotic in clinical trials. Interestingly progestogen 
receptors are membrane rather than nuclear and it may be that there are signalling pathways 
enabling crosstalk between the effects of the hormones on coagulation factor expression. It does 
have to be appreciated however that this is a complicated process of regulation and remains poorly 
understood. Finally, some effects of progestogens appear to be prothrombotic and some 
antithrombotic. This is why measuring thrombin generation is so important to be able to establish a 
phenotypic overview of the thrombotic state. 
 
Limitations 
We had very small numbers of individuals who could be assessed and it is possible with greater 
numbers that significant changes in coagulation factor and hormone levels could have been seen at 
an even earlier gestation than demonstrated in our work. This is particularly true of the hormone 
measurements where many women did not have sufficient plasma available to undertake these 
analyses. Sufficient plasma was available from most women for most of the coagulation factor 
assays. However, the hormonal assays were the last analyses to be undertaken at which point, for a 
number of women, there was insufficient plasma remaining. At Study Day +7 only 4 women had 
sufficient plasma to assess estradiol levels. With such small numbers a very large change in estradiol 
levels between the pre pregnant and pregnant state would have been required to demonstrate a 
significant increase. This is demonstrated by the fact that although estradiol levels had increased 
from pre pregnancy levels at Day +7 by 67% with very narrow confidence intervals, this was not a 
statistically significant change.  
These women were not undergoing an entirely natural conception and it is possible this could have 
had an impact on the results. Firstly, these women had poor fertility although women were only 
selected if the pregnancy being studied resulted in an entirely normal outcome for both mother and 
baby. Secondly, embryos were being transferred and therefore the process of in vivo fertilization and 
conception did not occur and it cannot be entirely ruled out that certain mechanisms occur during 
spontaneous fertilization and conception which affect coagulation and hormonal levels. However, 
during this early stage of pregnancy, no exogenous hormones were administered to these women 
and the corpus luteum is responsible for hormonal production, both progesterone and estradiol. 
There is no reason to assume that the function of the corpus luteum in these women was different 
to that which would occur with a ‘natural’ conception.   
Conclusion 
Overall, we are the first to establish that the onset of the prothrombotic state occurs at a very early 
stage of pregnancy, within the first few weeks of gestation. We have also provided further evidence 
that the development of the prothrombotic state is likely due to the combined effect of estradiol 
and progestogens on coagulation factor production. This work would suggest that the increased risk 
of thrombosis beings very early in pregnancy.  For this reason, consideration should be given to 
commencing thromboprophylaxis as early as possible in pregnancy, in women deemed at high risk of 
venous thrombosis.  
By characterising coagulation and hormonal profiles in normal women, this enables the 
development of further work to try and establish whether the coagulation cascade influences poor 
pregnancy outcomes. Assessing individual components of the coagulation cascade has to date been 
ineffective at predicting poor pregnancy outcome. However, with the characterisation of thrombin 
generation, a global assay of coagulation, in early pregnancy, its role as a potential predictor of 
subsequent poor pregnancy outcome e.g. recurrent pregnancy loss, pre-eclampsia could now be 
investigated with subsequent manipulation of abnormal thrombin generation patterns to determine 
whether poor outcomes can be reduced or averted.  
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